Your browser is no longer supported. Please, upgrade your browser.
Renalytix AI plc
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand36.02M Perf Week-2.34%
Market Cap1.04B Forward P/E- EPS next Y-0.33 Insider Trans- Shs Float5.88M Perf Month-2.62%
Income- PEG- EPS next Q-0.12 Inst Own16.50% Short Float8.01% Perf Quarter-2.62%
Sales1.02M P/S1020.34 EPS this Y72.30% Inst Trans0.25% Short Ratio5.83 Perf Half Y14.78%
Book/sh2.41 P/B12.47 EPS next Y- ROA- Target Price- Perf Year98.61%
Cash/sh2.15 P/C13.96 EPS next 5Y- ROE- 52W Range9.91 - 35.71 Perf YTD87.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.85% Beta-
Dividend %- Quick Ratio21.20 Sales past 5Y- Gross Margin- 52W Low203.33% ATR2.08
Employees17 Current Ratio21.20 Sales Q/Q- Oper. Margin- RSI (14)49.15 Volatility9.01% 7.21%
OptionableYes Debt/Eq0.01 EPS Q/Q-305.60% Profit Margin- Rel Volume1.16 Prev Close31.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume80.75K Price30.05
Recom- SMA202.55% SMA50-3.19% SMA20027.95% Volume93,700 Change-5.06%
Jul-02-21Initiated Berenberg Buy $38
Aug-11-20Initiated Stifel Buy
Jul-28-21 07:00AM  
Jul-26-21 07:00AM  
Jul-22-21 07:00AM  
Jul-16-21 06:19AM  
Jul-11-21 08:43AM  
Jun-28-21 07:00AM  
Jun-15-21 07:00AM  
Jun-10-21 08:00AM  
Jun-07-21 07:00AM  
Jun-03-21 07:00AM  
Jun-02-21 11:34AM  
May-19-21 07:00AM  
May-04-21 02:20PM  
Apr-22-21 07:00AM  
Apr-20-21 07:21AM  
Apr-14-21 07:00AM  
Apr-08-21 07:00AM  
Apr-05-21 07:00AM  
Mar-15-21 07:00AM  
Mar-10-21 10:31AM  
Mar-04-21 01:00PM  
Mar-02-21 07:00AM  
Feb-24-21 08:00AM  
Feb-23-21 02:00AM  
Feb-10-21 11:31AM  
Feb-08-21 07:30AM  
Feb-04-21 07:00AM  
Jan-13-21 02:00AM  
Jan-06-21 08:54AM  
Jan-05-21 06:00AM  
Jan-04-21 08:05AM  
Nov-29-20 11:42AM  
Nov-25-20 07:30AM  
Nov-13-20 02:00AM  
Nov-06-20 07:00AM  
Nov-02-20 10:30AM  
Oct-28-20 07:30AM  
Oct-27-20 03:00AM  
Oct-26-20 07:30AM  
Sep-22-20 07:00AM  
Sep-18-20 07:00AM  
Aug-26-20 07:00AM  
Aug-21-20 03:00AM  
Aug-03-20 08:00AM  
Jul-27-20 08:00AM  
Jul-21-20 03:57PM  
Jul-16-20 11:38PM  
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.